Australia's century of meningococcal disease: development and the changing ecology of an accidental pathogen.
Trends in meningococcal disease (MD) over the 20th century in Australia, as in other industrialised countries, have been characterised by epidemics during the two World Wars, a transient rise in incidence in the 1950s followed by endemic disease, and in the 1980s the emergence of a sustained hypersporadic phase. Epidemics occur at times of social upheaval and among marginalised populations, and resolve when living conditions improve. Periodic serogroup A epidemics have been replaced since the 1950s by endemic disease caused mainly by serogroups B and C meningococci. The current hypersporadic plateau in Australia, as in other industrialised countries, is associated with the intercontinental spread of hypervirulent clones of meningococci. The conjugate serogroup C vaccine has reduced the incidence of MD and carriage rates of serogroup C meningococci. However, the vaccine is expensive and its long-term impact on the emergence of non-vaccine strains and on nasopharyngeal microecology is unknown. A rising incidence of MD should not be viewed as the action of a virulent microbe exploiting a vulnerable population, but as the emergence of an "accidental pathogen" from an evolving host-microbial ecology. While it is essential to monitor the impact of vaccines on this ecology, we must find ways that can optimise our coexistence with microbes.
Patel
Mahomed S
MS
National Centre for Epidemiology and Population Health, Australian National University, Canberra, ACT. mahomed.patel@anu.edu.au
D001315:Australia / Q000453:epidemiology; D003362:Cost-Benefit Analysis; D018563:Disease Notification; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D008589:Meningococcal Infections / Q000453:epidemiology* / Q000266:history / Q000517:prevention & control; D022401:Meningococcal Vaccines / Q000191:economics* / Q000276:immunology; D009345:Neisseria meningitidis / Q000187:drug effects / Q000472:pathogenicity; D018074:Vaccines, Conjugate
D022401:Meningococcal Vaccines; D018074:Vaccines, Conjugate; C410218:serogroup C meningococcal conjugate vaccine